AbbVie 4Q Revenue Rises on Immunology Growth
By Nicholas G. Miller
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio.
The company reported net income of $1.82 billion, or $1.02 a share, compared with a loss of $22 million, or 2 cents a share, the year prior.
Adjusted earnings were $2.71 a share. Analysts polled by FactSet had expected $2.65 a share.
Net revenue rose 10% to $16.62 billion. Wall Street had expected $16.41 billion. Immunology revenue was up 18% at $8.63 billion, while neuroscience revenue climbed 18% to $2.96 billion.
AbbVie's immunology portfolio was led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq, for which revenue rose 32.5% and 29.5% respectively. That offset a 26% decline for immune-disease therapy Humira, which is facing competition from cheaper copycats.
The company guided for 2026 adjusted earnings of $14.37 to $14.57 a share. Analysts see 2026 adjusted earnings of $14.27 a share.
Write to Nicholas G. Miller at nicholas.miller@wsj.com
(END) Dow Jones Newswires
February 04, 2026 08:20 ET (13:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
United States